← Eichor
Condition: Mibc Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Mibc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Phase 1/Phase 2 · 59 location(s) · Janssen Research & Development, LLC · NCT05316155Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
NA · 2 location(s) · Johns Hopkins University · NCT07225205Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Phase 2 · 12 location(s) · Fujian Medical University Union Hospital · NCT07296705Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Phase 2 · 1 location(s) · Leslie Ballas · NCT06417190Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
Phase N/A · 1 location(s) · Assiut University · NCT07202845Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Phase 2 · 5 location(s) · Matthew Galsky · NCT06809140Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Phase 2/Phase 3 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT06879145Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
Phase 2 · 1 location(s) · University of California, Irvine · NCT06682728EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
Phase 2 · 1 location(s) · Peking University Third Hospital · NCT07647289Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
Phase 1 · 1 location(s) · Shilpa Gupta, MD · NCT05833867Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
Phase 3 · 1 location(s) · University of Rome Tor Vergata · NCT07067749A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Mi
Phase N/A · 1 location(s) · Peking University First Hospital · NCT06991868Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Gro
Phase 2 · 23 location(s) · Spanish Oncology Genito-Urinary Group · NCT06511648A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging
Phase N/A · 1 location(s) · Oslo University Hospital · NCT07602010Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasiv
Phase 2 · 1 location(s) · University Hospital, Ghent · NCT04724928RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
Phase 1/Phase 2 · 1 location(s) · Zhujiang Hospital · NCT06341400Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
Phase 2 · 1 location(s) · Peking University First Hospital · NCT05072600Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC
Phase 3 · 22 location(s) · Zhiquan Hu · NCT07693959Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
Phase 2 · 4 location(s) · Kyoto University Hospital · NCT05879653
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.